Yvonne Diaz: EU Medicines Agency has approved Alecensa (alectinib) for early stage stage ALK+ lung cancer

Yvonne Diaz, Co-founder of Oncogene Cancer Research, shared a post on X:

“Great to see that EU Medicines Agency has approved Alecensa (alectinib) for early stage stage ALK+ lung cancer following the success of the ALINA clinical trial.

This highlights the need for biomarker testing across all stage non-small cell lung cancer patients.”

Additional information.
Source: Yvonne Diaz/X